20.500.12556/DiRROS-28626 Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis Objectives: In axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating secukinumab, we aimed to assess retention rates and proportions of patients achieving remission and low disease activity (LDA), according to disease activity measures and patient-reported outcomes at 24 and 48 months. Patients and methods: Data on patients with axSpA and PsA who initiated secukinumab treatment were pooled from 13 European registries. Analyses were performed overall and stratified according to the number of previous biologic/targeted synthetic Disease-Modifying Antirheumatic Drugs (b/tsDMARDs, 0/1/≥ 2). Kaplan-Meier plots and Cox regression analyses were performed to assess and compare secukinumab retention rates. Comparisons of remission and LDA rates were performed by logistic regression analyses. Results: The overall 24-/48-month secukinumab retention rates were 61%/51% in 767 axSpA patients, and 64%/49% in 975 PsA patients, respectively. Compared to b/tsDMARD naïve patients, a higher risk of withdrawal from secukinumab was found for those with ≥ 2 prior b/tsDMARDs in axSpA and PsA, and 1 prior b/tsDMARD in axSpA. Generally, remission and LDA rates were numerically higher in b/tsDMARD naïve patients. After adjustment for confounders, statistically significantly higher remission and LDA rates were found for b/tsDMARD naïve patients compared to patients with ≥ 2 prior b/tsDMARDs at 24 months in axSpA and PsA. Conclusion: This large European real-world study demonstrates that 4-year secukinumab retention rates were approximately 50% in both axSpA and PsA. b/tsDMARD naïve patients had higher retention, remission and LDA rates than patients with prior b/tsDMARD exposure. bDMARD epidemiology spondyloarthritis epidemiologija spondiloartritis true false true Angleški jezik Slovenski jezik Neznano 2026-03-26 13:22:09 2026-03-26 13:22:10 2026-03-28 03:51:18 0000-00-00 00:00:00 2025 0 0 str. 1-13 iss. 3,[article no.] 105824 Vol. 92 May 2025 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616-002 1297-319X 10.1016/j.jbspin.2024.105824 218928131 RAZ_Pons_Marion_2025.pdf RAZ_Pons_Marion_2025.pdf 1 0F818B9F0EF11F753534EE39C4AE8257 190b76f5a1765b8138075b8c6c8d732034ebce9545e234e9c7452d0e5a45927d a759c467-290e-11f1-aa40-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=42531 https://www.sciencedirect.com/science/article/pii/S1297319X24001350?via%3Dihub 1 6c4cb3f7-290e-11f1-aa40-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=42530 Univerzitetni klinični center Ljubljana 0 0 0